Celldex Q1 net loss widens to $53.8M; Phase 3 CSU enrollment ongoing, multiple data readouts in 2025

Celldex Therapeutics, Inc.

2025-Q1 EPS reported -$0.81 revenue$695,000

Net loss of $53.8M ($0.81/share) vs $32.8M ($0.56/share) in Q1 2024; R&D expenses rose to $52.6M.
Cash, equivalents and marketable securities $673.3M at March 31, sufficient to fund operations through 2027.
Phase 3 barzolvolimab CSU studies (EMBARQ-CSU1/2) enrolling; Phase 2 EoE enrollment complete; data expected 2025.
76-week CSU Phase 2 data accepted for late-breaking oral presentation at EAACI June 2025.
Bispecific CDX-622 Phase 1 in healthy volunteers enrolling; Part 1 data expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.